Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer
Clinical trial NCT05764941 · UNKNOWN
Trial details
- NCT number
- NCT05764941
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2020-01-01
- Primary completion
- 2024-03-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.